118 related articles for article (PubMed ID: 15446795)
21. A systematic study of imaging uncertainties and their impact on 125I prostate brachytherapy dose evaluation.
Lindsay PE; Van Dyk J; Battista JJ
Med Phys; 2003 Jul; 30(7):1897-908. PubMed ID: 12906208
[TBL] [Abstract][Full Text] [Related]
22. Dosimetric effects of seed anisotropy and interseed attenuation for 103Pd and 125I prostate implants.
Chibani O; Williamson JF; Todor D
Med Phys; 2005 Aug; 32(8):2557-66. PubMed ID: 16193786
[TBL] [Abstract][Full Text] [Related]
23. Is it necessary to eliminate the posterior dose margin in prostate brachytherapy to achieve an acceptably low risk of late rectal morbidity?
Waterman FM; Dicker AP
Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):293-9. PubMed ID: 12909246
[TBL] [Abstract][Full Text] [Related]
24. Relating the proton relative biological effectiveness to tumor control and normal tissue complication probabilities assuming interpatient variability in α/β.
Paganetti H
Acta Oncol; 2017 Nov; 56(11):1379-1386. PubMed ID: 28918679
[TBL] [Abstract][Full Text] [Related]
25. A detailed radiobiological and dosimetric analysis of biochemical outcomes in a case-control study of permanent prostate brachytherapy patients.
Butler WM; Stewart RR; Merrick GS
Med Phys; 2009 Mar; 36(3):776-87. PubMed ID: 19378738
[TBL] [Abstract][Full Text] [Related]
26. Effect of edema, relative biological effectiveness, and dose heterogeneity on prostate brachytherapy.
Wang JZ; Mayr NA; Nag S; Montebello J; Gupta N; Samsami N; Kanellitsas C
Med Phys; 2006 Apr; 33(4):1025-32. PubMed ID: 16696479
[TBL] [Abstract][Full Text] [Related]
27. Viability of the EUD and TCP concepts as reliable dose indicators.
Ebert MA
Phys Med Biol; 2000 Feb; 45(2):441-57. PubMed ID: 10701514
[TBL] [Abstract][Full Text] [Related]
28. Determination of the prescription dose for biradionuclide permanent prostate brachytherapy.
Nuttens VE; Lucas S
Med Phys; 2008 Dec; 35(12):5451-62. PubMed ID: 19175105
[TBL] [Abstract][Full Text] [Related]
29. How low is the alpha/beta ratio for prostate cancer?
Wang JZ; Guerrero M; Li XA
Int J Radiat Oncol Biol Phys; 2003 Jan; 55(1):194-203. PubMed ID: 12504054
[TBL] [Abstract][Full Text] [Related]
30. The use of spatial dose gradients and probability density function to evaluate the effect of internal organ motion for prostate IMRT treatment planning.
Jiang R; Barnett RB; Chow JC; Chen JZ
Phys Med Biol; 2007 Mar; 52(5):1469-84. PubMed ID: 17301465
[TBL] [Abstract][Full Text] [Related]
31. Tumor control probability (TCP) in prostate cancer: role of radiobiological parameters and radiation dose escalation.
Ahmad S; Vogds BJ; McKenna F; Vlachaki MT
J Xray Sci Technol; 2009; 17(4):347-54. PubMed ID: 19923690
[TBL] [Abstract][Full Text] [Related]
32. Optimal radiotherapy for prostate cancer: predictions for conventional external beam, IMRT, and brachytherapy from radiobiologic models.
King CR; DiPetrillo TA; Wazer DE
Int J Radiat Oncol Biol Phys; 2000 Jan; 46(1):165-72. PubMed ID: 10656389
[TBL] [Abstract][Full Text] [Related]
33. Calculated and simulated effects of heterogeneous dose distributions in radiotherapy using the dose volume inhomogeneity corrected biological equivalent dose formula with special reference to prostate cancer.
Lennernäs B; Albertsson P; Edgren M; Nilsson S
Oncol Rep; 2007 Nov; 18(5):1299-303. PubMed ID: 17914588
[TBL] [Abstract][Full Text] [Related]
34. Dosimetry accuracy as a function of seed localization uncertainty in permanent prostate brachytherapy: increased seed number correlates with less variability in prostate dosimetry.
Su Y; Davis BJ; Furutani KM; Herman MG; Robb RA
Phys Med Biol; 2007 Jun; 52(11):3105-19. PubMed ID: 17505092
[TBL] [Abstract][Full Text] [Related]
35. [Intraoperative and post-implant dosimetry in patients treated with permanent prostate implant brachytherapy].
Herein A; Ágoston P; Szabó Z; Jorgo K; Markgruber B; Pesznyák C; Polgár C; Major T
Magy Onkol; 2015 Jun; 59(2):148-53. PubMed ID: 26035163
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of the dose distribution for prostate implants using various 125I and 103Pd sources.
Meigooni AS; Luerman CM; Sowards KT
Med Phys; 2009 Apr; 36(4):1452-8. PubMed ID: 19472652
[TBL] [Abstract][Full Text] [Related]
37. The effects of radiotherapy treatment uncertainties on the delivered dose distribution and tumour control probability.
Booth JT; Zavgorodni SF
Australas Phys Eng Sci Med; 2001 Jun; 24(2):71-8. PubMed ID: 11560173
[TBL] [Abstract][Full Text] [Related]
38. Quantifying the effect of dose inhomogeneity in brachytherapy: application to permanent prostatic implant with 125I seeds.
Ling CC; Roy J; Sahoo N; Wallner K; Anderson L
Int J Radiat Oncol Biol Phys; 1994 Mar; 28(4):971-8. PubMed ID: 8138450
[TBL] [Abstract][Full Text] [Related]
39. Moving toward focal therapy in prostate cancer: dual-isotope permanent seed implants as a possible solution.
Todor DA; Barani IJ; Lin PS; Anscher MS
Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):297-304. PubMed ID: 21536392
[TBL] [Abstract][Full Text] [Related]
40. Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I based on radiobiological effectiveness and dosimetry.
Dicker AP; Lin CC; Leeper DB; Waterman FM
Semin Urol Oncol; 2000 May; 18(2):152-9. PubMed ID: 10875458
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
